NCT02622113View on ClinicalTrials.gov

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Canagliflozin (TA-7284)

The patients will receive Canagliflozin orally for 36 weeks

DRUG

Insulin

Trial Locations (7)

Unknown

Reserch site, Chugoku

Reserch site, Chūbu

Reserch site, Hokkaido

Reserch site, Kanto

Reserch site, Kinki

Reserch site, Kyushu

Reserch site, Tōhoku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY